Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Dynafucin
 

DESCRIPTION

Dynafucin 125 Tablet

Colour : White

Shape : Round, Biconvex & Scored

Each tablet contains : Griseofulvin .......................125 mg

 

Dynafucin 500 Tablet

Colour White

Shape : Round, Flat & Scored

Marking "GF"

Each tablet contains : Griseofulvin .......................500 mg


PHARMACODYNAMICS
Griseofulvin is an antifungal antibiotic which is reported to be deposited in keratin in fungistatic concentrations. It exerts an inhibitory action in vitro against the common dermatophytes, including Epidermophyton floccosum, Micosporum spp., and Trichophyton spp. The inhibitory action has been reported in concentrations of 0.14 to 5 mcg/mL through 15 mcg or more per mL has on occasion been necessary.

 

PHARMACOKINETICS

Griseofulvin is irregularly absorbed from the gastrointestinal tract. It is deposited in keratin precursor cells and is concentrated in the stratum corneum of the skin and in the nails and hair, thus preventing fungous invasion of newly formed cells. Griseofulvin is metabolised by the liver mainly to 6-demethylgriseofulvin which is excreted in the urine. A large amount of a dose of Griseofulvin is excreted unchanged in the faeces and a small amount in the urine; some is excreted in the sweat. The absorption of Griseofulvin can be increased by administration with a fatty meal or a glass of milk or by reducing its particle size.

 

INDICATION

It is used in the treatment of tinea (ringworm) infections caused by various species of Epidermophyton, Microsporum and Trichophyton. It is given for tinea infections of the scalp, hair, nails and skin and which do not respond to topical treatment.

 

RECOMMENDE DOSE

Adults : 0.5 to 1 g daily ins ingle or divided doses.

Children : 10 mg per kg body weight daily

(To be taken with or after meals)

The duration of treatment depends on the thickness of the keratin layer: 2 to 6 weeks for infection of the hair and skin, 6 to 9 months for infections of the finger nails, and 12 to 18 months for infections of the toe-nails.

 

CONTRAINDICATION

Griseofulvin is contraindicated in patients with porphyria and liver failure, and should be used with extreme caution inpatients with systemic lupus erythematosus.

 

WARNING AND PRECAUTIONS

Laboratory studies have shown that Griseofulvin may damage sperm cell, males should not father children within 6 months of treatment.

 

DRUG INTERACTIONS

Griseofulvin may diminish the effects of coumarin anticoagulants and oral contraceptives possibly by increasing their rate of metabolism. Phenobarbitone has been reported to decrease the gastrointestinal absorption of Griseofulvin, and therefore the effects of may be diminished by concurrent therapy with barbiturates.

 

PREGNANCY AND LACTATION

The use of Griseofulvin in pregnancy is not recommended.

 

SIDE EFFECTS/ADVERSE REACTIONS

Side effects are usually mild and transient and consist of headache, skin rashes, dryness of the mouth, an altered sensation of taste and gastrointestinal disturbances. Angioedema, erythema multiforme, exfoliative dermatitis, proteinuria, leucopenia and other blood dyscrasias, candidiasis, paraesthesia, photosensitisation, and severe headache have been reported occasionally. Depression, confusion, dizziness, insomnia, and fatigue have also been reported. Abnormalities of the sexual organs and breasts have occurred, especially in children. There have been a few reports of hepatotoxicity attributed to Griseofulvin.

 

SYMPTOMS AND TREATMENT OF OVERDOSE

Symptoms of overdose include headache, dizziness, nausea, vomiting, skin rash, confusion and itching (hypersensitivity). Treatment is by gastric lavage and supportive and symptomatic treatment. Emetics may be tried if the patient is alert.

 

PACKING/PACK SIZES

Dynafucin 125 Tablet

Plastic container of 1000's (For EXPORT/TENDER Only).

Blister pack of 10 x 10's.

 

Dynafucin 500 Tablet

Plastic container of 500's (For EXPORT/TENDER Only).

Blister pack of 10 x 10's.

 

SHELF LIFE

3 years from the date of manufacture.


STORAGE CONDITIONS
KEEP OUT OF REACH OF CHILDREN

Keep Container Tightly Closed

Store In A Dry Place Below 25C

Protect From Light

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer